Literature DB >> 18455217

Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction.

Antonius A C M Heestermans1, Jochem W van Werkum, Dirk Taubert, Toine H Seesing, Nicolas von Beckerath, Christian M Hackeng, Edgar Schömig, F W A Verheugt, Jurriën M ten Berg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18455217     DOI： 10.1016/j.thromres.2008.01.021

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  30 in total

1.  Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.

Authors:  Dimitrios Alexopoulos; Nikolaos Barampoutis; Vasileios Gkizas; Chrysoula Vogiatzi; Grigorios Tsigkas; Nikolaos Koutsogiannis; Periklis Davlouros; George Hahalis; Sven Nylander; Guido Parodi; Ioanna Xanthopoulou
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

Review 2.  Genetics of platelet inhibitor treatment.

Authors:  Dietmar Trenk; Willibald Hochholzer
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

3.  Impaired bioavailability and antiplatelet effect of high-dose clopidogrel in patients after cardiopulmonary resuscitation (CPR).

Authors:  L Součková; R Opatřilová; P Suk; I Čundrle; M Pavlík; V Zvoníček; O Hlinomaz; V Šrámek
Journal:  Eur J Clin Pharmacol       Date:  2012-08-14       Impact factor: 2.953

Review 4.  An Updated Protocol for Evaluating Chest Pain and Managing Acute Coronary Syndromes.

Authors:  Christopher R Kelly; Ajay J Kirtane; Jennifer Stant; Gregg W Stone; Robert M Minutello; S Chiu Wong; Honeyleen Manuzon; Roxanne Gerow-Smith; Nancy Kelley; LeRoy E Rabbani
Journal:  Crit Pathw Cardiol       Date:  2017-03

Review 5.  Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.

Authors:  Ana Lucrecia Marcano; José Luis Ferreiro
Journal:  Curr Atheroscler Rep       Date:  2016-11       Impact factor: 5.113

6.  Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI?

Authors:  Kush Agrawal; Deepak L Bhatt
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

7.  RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction.

Authors:  Jihong Li; Spandana Vootukuri; Yi Shang; Ana Negri; Jian-Kang Jiang; Mark Nedelman; Thomas G Diacovo; Marta Filizola; Craig J Thomas; Barry S Coller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-08-21       Impact factor: 8.311

8.  Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.

Authors:  Dimitrios Alexopoulos; Angelos Perperis; Ioanna Koniari; Haralambos Karvounis; Sotirios Patsilinakos; Antonios Ziakas; Nikolaos Barampoutis; Theofilos Panagiotidis; Karolina Akinosoglou; George Hahalis; Ioanna Xanthopoulou
Journal:  J Thromb Thrombolysis       Date:  2015-10       Impact factor: 2.300

9.  The platelet: life on the razor's edge between hemorrhage and thrombosis.

Authors:  Barry S Coller
Journal:  Transfusion       Date:  2014-08-05       Impact factor: 3.157

10.  Impact of mild hypothermia on platelet responsiveness to aspirin and clopidogrel: an in vitro pharmacodynamic investigation.

Authors:  José Luis Ferreiro; José Carlos Sánchez-Salado; Montserrat Gracida; Ana Lucrecia Marcano; Gerard Roura; Albert Ariza; Josep Gómez-Lara; Victoria Lorente; Rafael Romaguera; Sílvia Homs; Guillermo Sánchez-Elvira; Luis Teruel; Kristian Rivera; Silvia Gabriela Sosa; Joan Antoni Gómez-Hospital; Dominick J Angiolillo; Angel Cequier
Journal:  J Cardiovasc Transl Res       Date:  2013-12-21       Impact factor: 4.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.